EP: 1.Current Front-Line Treatment Options for CLL in 2023 EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving...
Ibrutinibis an oral inhibitor of Bruton's tyrosine kinase that is indicated for CLL in patients who are treatment-naïve or have been previously treated.[14,15,16,17]It is also indicated for patients who carry a deletion in chromosome 17 (del 17p CLL), which is associated with poor resp...
Also, it is because there are so many gaps where we're trying to find the best, most cohesive treatment options for patients.[The biggest challenge is] trying to help patients navigate areas where there is no mature research in terms of: how do the novel agents in the frontline setting d...
Treatment Options for CLL: An Expert RoundtableJennifer R. Brown
Here are some of the options your doctor will consider. You may also take other types of medicines to help prevent complications, such as to prevent infections while you’re going through treatment. CLL Treatments Chemotherapy for CLL These drugs disrupt the life cycle of cancer cells. They dam...
[2]Malcikova, Jitka et al. “Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.” Blood vol. 138,25 (2021): 2670-2685. doi:10.1182/blood.2020009...
The first step of that marathon involves learning about your cancer and your treatment options. You've Been Diagnosed: Now What? DID YOU KNOW? Most blood cancer doctors in the United States determine the stage of a patient’s CLL based on the Rai system. It divides CLL into five stages ...
Pharmacy Times:What is the process for identifying the best treatment for an individual patient with CLL, which can be complex in this patient population? Ciervo:Yeah, I feel like—especially since this is like a diagnosis of elderly patients—people can have a ton of comorbidities [and take]...
Blood, 142 (suppl 1) (2023), p. 3706 View PDFView articleCrossrefGoogle Scholar 7 A Chatterjee, S Shapouri, BS Manzoor, et al. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the Unit...
June 1st 2023 Podcast In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space. Listen Hoffmann Examines Data for 17p Deletion in Treatment-Naive CLL Targeted Oncology Staff ...